Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

In the latest close session, Viking Therapeutics, Inc. (VKTX) was down 9.32% at $32.12. The stock trailed the S&P 500, which registered a daily gain of 0.64%. At the same time, the Dow added 1.23%, and the tech-heavy Nasdaq gained 0.69%. The company's shares have seen a decrease of 8.12% over the last month, not keeping up with the Medical sector's gain of 0.63% and the S&P 500's gain of 0.55%.The investment community will be closely monitoring the performance of Viking Therapeutics, Inc. in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be -$0.89, reflecting a 178.13% decrease from the same quarter last year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$2.68 per share and revenue of $0 million. These totals would mark changes of -165.35% and 0%, respectively, from last year. It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.21% fall in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. currently has a Zacks Rank of #4 (Sell). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks